Regenerative science, laboratory development and responsible clinical translation
EspañolCELLMEX is a regenerative medicine platform integrating scientific research, laboratory manufacturing, physician education, clinical collaboration and advanced patient-care programmes.
Research. Manufacturing. Clinical Translation. Engineering the Future of Regenerative Medicine.
CELLMEX is a regenerative medicine and biotechnology organisation focused on the responsible development and clinical translation of advanced cellular and cell-free biological technologies.
Our platform brings together laboratory research, biological process development, clinical medicine, physician collaboration, scientific education and structured patient-care programmes.
This integrated structure allows CELLMEX to examine a technology from several perspectives: biological identity, laboratory processing, quality control, clinical relevance, patient eligibility, administration, monitoring and long-term follow-up.
Our work includes mesenchymal stromal cells, extracellular vesicles, exosome-related technologies, MSC secretome, conditioned media, exosome-depleted conditioned media, tissue-directed cellular systems and selected immune-cell technologies.
CELLMEX exists to advance regenerative medicine through the integration of scientific research, laboratory formulation and manufacturing, physician collaboration and responsible clinical translation, enabling patients and healthcare professionals to access advanced biologic technologies developed under rigorous scientific and quality standards.
To remain one of the leading regenerative medicine platforms serving physicians and patients throughout Latin America by advancing scientifically validated cellular and cell-free biologic technologies through research, manufacturing, education and responsible clinical application.
CELLMEX connects scientific discovery with practical laboratory development and responsible patient care.
In-vitro, ex-vivo, translational and clinically informed research examining cellular biology, extracellular vesicles, secreted factors, formulation and biological function.
Development of reproducible laboratory processes, biological preparation methods, preservation systems, documentation and quality controls.
Cooperation with physicians, specialists, clinics, hospitals and researchers to support informed clinical decision-making and appropriate patient pathways.
Careful movement from biological concept to physician-supervised clinical consideration, informed consent, administration, monitoring and follow-up.
Scientific and clinical claims should be supported by appropriate evidence, biological rationale and transparent qualification—not promotional hype.
Clinical decisions should follow appropriate medical evaluation, realistic risk assessment, informed consent and ethical professional practice.
Emerging technologies should be adopted through scientific evaluation, documented development, regulatory awareness and clearly defined clinical limitations.
Biological preparation requires attention to quality systems, source-material traceability, reproducible processes, storage and documentation.
CELLMEX works with healthcare professionals to support diagnosis-specific evaluation, informed treatment planning and continuity of patient care.
We remain committed to laboratory development, translational science, scientific collaboration and the responsible evaluation of emerging biologic technologies.
Identify a clinical need, biological mechanism or technology opportunity and examine the existing evidence, limitations and development requirements.
Establish source materials, process conditions, identity, characterisation, formulation, preservation and quality-related criteria.
Determine whether a technology has a medically supportable role for a specific patient, indication or clinical programme.
Implement eligible applications through physician oversight, informed consent, appropriate clinical facilities and structured follow-up.
Dr. Patino Cohen's experience in stem-cell- related research, regenerative medicine and clinical operations dates to 1994.
His work has included the evaluation and development of cellular technologies, clinical treatment programmes, laboratory operations, patient-care pathways and collaboration with physicians and scientific colleagues.
The CELLMEX leadership model is informed not only by clinical medicine, but also by experience involving speciality pharmaceuticals, biological products, manufacturing, international distribution and regulated-market development.
This broader operational perspective supports a more disciplined approach to biological-product identity, source materials, documentation, quality, storage, transport and clinical use.
The role of the lead investigator is not to promise that every emerging technology will succeed. It is to identify what is scientifically plausible, determine what can be responsibly developed and ensure that uncertainty is communicated clearly.
The chronology below describes the general development of the CELLMEX leadership experience and platform. More detailed dates and milestones should be added only where supported by institutional records.
Dr. Giorgio Patino Cohen began work involving stem-cell-related science, regenerative medicine concepts and clinical operations.
Experience expanded to include physician-led patient review, clinical programme design, treatment coordination and longitudinal follow-up.
The platform evolved to incorporate laboratory development, cellular processing, cell-free biologics and technical process evaluation.
CELLMEX expanded its scientific scope to include MSCs, extracellular vesicles, exosome-related preparations, secretome, conditioned media and tissue-directed cellular research.
CELLMEX is being developed as a research, manufacturing, clinical and educational platform serving physicians, institutions and patients in Mexico and selected Latin American markets.
Mexico serves as the principal base for CELLMEX clinical operations, laboratory development, physician collaboration and patient services.
CELLMEX seeks to develop relationships with physicians, clinics, hospitals, laboratories, researchers and patients throughout selected Latin American markets.
Brazil requires a dedicated Portuguese-language, scientific, regulatory and commercial strategy developed with appropriately qualified local partners.
We distinguish laboratory findings, clinical observations, published evidence and investigational hypotheses rather than presenting them as equivalent.
We do not guarantee cures, permanent tissue regeneration, reversal of progressive disease or predetermined clinical outcomes.
Treatment consideration begins with diagnosis, medical history, previous care, current health status and review of appropriate alternatives.
Biological technologies require attention to source materials, preparation records, handling, storage, documentation and process consistency.
We support communication with referring and treating physicians to maintain continuity of care and diagnosis-specific medical oversight.
Laboratory methods, clinical pathways and scientific interpretations are reviewed as new evidence, technologies and quality requirements emerge.
CELLMEX is committed to presenting the professional experience of its investigators accurately. The statement that Dr. Giorgio Patino Cohen's stem-cell-related and clinical operations experience dates to 1994 reflects his professional history.
Specific claims concerning scientific discoveries, patents, formal academic appointments, published research, institutional affiliations or influence on other investigators should be published only when they can be supported by appropriate records.
This approach protects both scientific credibility and the integrity of the CELLMEX platform.
Explore our research, technologies, laboratory, clinical programmes and professional collaboration pathways.